Efficacy of Pirfenidone According to Dose in Patients with Idiopathic Pulmonary Fibrosis: A Prospective, Observational, Single-Center Cohort Study.
Ho Young LeeSo Young JungJi Hoon JangJunghae KoDae-Wook KimMinyoung HerJae Ha LeePublished in: Life (Basel, Switzerland) (2023)
In our study, regardless of dose, consistent pirfenidone use for 12 months resulted in similar efficacy for the prevention of disease progression in patients with IPF. Large-scale, randomized, double-blind, placebo-controlled clinical trials are needed.